A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/55 (2006.01) A61K 9/20 (2006.01) A61K 31/407 (2006.01) A61K 31/435 (2006.01) A61K 31/473 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2251114
The present invention relates to the use of pharmaceutically acceptable cholinesterase inhibitors for the preparation of a pharmaceutical composition for the treatment or prophylaxis of arthritic disorders, including osteoarthritis, rheumatoid arthritis and other rheumatoid diseases such as Juvenile Arthritis, Systemic Lupus Erythematosis, Sjögren's Syndrome, Progressive Systemic Sclerosis, Polymyositis, Dermatomyositis, Ankylosing Spondilitis, Reiter's Syndrome, Psoriatic Arthritis, Relapsing Polychondritis, Relapsing Panniculitis, Crohn's Disease, Ulcerative Colitis, Hereditary Complement Deficiencies, Collagen Vascular Diseases, Felty's Syndrome, rheumatological manifestations associated with bacterial and viral endocarditis or myocarditis and other rheumatological manifestations such as anaemia of chronic disorders. The invention also relates to a novel method of treatment or prophylaxis of such diseases and manifestations. Preferably, the cholinesterase inhibitors are selected from a group of nicotinic acetylcholinesterase inhibitors such as galantamine (the name of this drug was previously spelled galanthamine).
Utilisation d'inhibiteurs de cholinestérase pharmaceutiquement acceptables dans la préparation d'une composition pharmaceutique destinée au traitement ou à la prévention des affections arthritiques, notamment l'arthrose, la polyarthrite rhumatoïde et les autres maladies rhumatoïdes telles que la polyarthrite juvénile, le lupus érythémateux disséminé, le syndrome de Sjögren, la sclérodermie systémique progressive, la polymyosite, la dermatomyosite, la spondylarthrite ankylosante, le syndrome conjonctivo-urétro-synovial de Fiessinger-Leroy, la polyarthrite psoriasique, la polychondrite récidivante, la panniculite récidivante, la maladie de Crohn, la colite ulcéreuse, le déficit en complément héréditaire, la collagénose avec manifestations vasculaires, le syndrome de Felty, les manifestations rhumatologiques associées à la myocardite ou endocardite bactérienne ou virale, et d'autres manifestations rhumatologiques telles que l'anémie ou les troubles chroniques. On a également prévu un nouveau procédé de traitement ou de prévention de maladies et manifestations de ce type. De préférence, les inhibiteurs de cholinestérase sont choisis dans le groupe des inhibiteurs d'acétylcholinestérase nicotinique tels que la galantamine (ancienne orthographe: galanthamine).
Murray James
Snorrason Ernir
Fetherstonhaugh & Co.
Snorrason Ernir
LandOfFree
Treatment of arthritis disorders, rheumatoid arthritis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of arthritis disorders, rheumatoid arthritis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of arthritis disorders, rheumatoid arthritis and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1834602